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Abstract
Background: The identification and treatment of LTBI is a key component of the WHO’s strategy to eliminate TB.
Recent migrants from high TB-incidence countries are recognised to be at risk TB reactivation, and many high-
income countries have focused on LTBI screening and treatment programmes for this group. However, migrants
are the group least likely to complete the LTBI cascade-of-care. This pragmatic cluster-randomised, parallel group,
superiority trial investigates whether a model of care based entirely within a community setting (primary care) will
improve treatment completion compared with treatment in specialist TB services (secondary care).
Methods: The CATAPuLT trial (Completion and Acceptability of Treatment Across Primary Care and the community
for Latent Tuberculosis) randomised 34 general practices in London, England, to evaluate the efficacy and safety of
treatment for LBTI in recent migrants within primary care. GP practices were randomised to either provide management
for LTBI entirely within primary care (GPs and community pharmacists) or to refer patients to secondary care. The target
recruitment number for individuals is 576. The primary outcome is treatment completion (defined as taking at least 90%
of antibiotic doses). The secondary outcomes assess adherence, acceptance of treatment, the incidence of adverse effects
including drug-induced liver injury, the rates of active TB, patient satisfaction and cost-effectiveness of LTBI treatment. This
protocol adheres to the SPIRIT Checklist.
Discussion: The CATAPuLT trial seeks to provide implementation research evidence for a patient-centred intervention to
improve treatment completion for LTBI amongst recent migrants to the UK.
Trial registration: NCT03069807, March 2017, registered retrospectively.
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Background
TB remains the leading cause of death among infectious
diseases globally [1]. The WHO strategy to eliminate TB
prioritises screening and treatment of those at high risk
of latent tuberculosis infection (LTBI) [2]. It is estimated
that approximately a quarter of the world’s population
(1.7 billion people) have LTBI [3]. Epidemiological mod-
elling indicates that without successful treatment of
LTBI in addition to active case finding it will be impos-
sible to eliminate TB by 2050 [4] .
Recent migrants from high TB-incidence countries are
recognized to be a group with a high LTBI prevalence
and risk of TB reactivation [5]. In many high-income
countries, where a high proportion of TB cases occur
amongst the foreign-born, TB strategies have focused on
LTBI screening and treatment programmes for this
group, including England, which in 2015 made the sys-
tematic screening and treatment of LTBI in migrants a
core component of its national TB control strategy [6].
However, traditional models of care are associated with
low rates of completion in the LTBI cascade-of-care,
with recent migrants recording the lowest rates of any
at-risk group [7]. Recognising the weaknesses of trad-
itional models of care, the End TB Strategy makes “inte-
grated, patient-centred care and prevention” a pillar of
its action-frame work for elimination and calls for ur-
gent “research to optimise implementation” of novel
strategies [2].
The London borough of Newham has been a pilot site
for the national LTBI screening programme for recent
migrants since 2014. Newham has the highest incidence
of active TB in the United Kingdom (UK), with 86% of
cases in 2014 occurring in those born outside the UK
[8]. The programme in Newham has adopted a novel
model of care for treating LTBI that occurs entirely
within the community: GPs offer screening with an
IGRA. Patients with positive results are assessed and if
diagnosed with LTBI offered treatment that is monitored
by a trained community pharmacist in collaboration
with the patient’s GP. This is the first time in the UK
that LTBI has been managed systematically outside of a
specialist TB service. The proposed national model for
LTBI screening in England is to screen for LTBI in pri-
mary care but for those identified with LTBI to be re-
ferred for assessment and treatment to secondary care
(specialist TB services) [9]. Specialist TB services for
Newham are provided by the TB clinic at Newham Uni-
versity Hospital, Barts Health NHS Trust.
We will conduct a pragmatic cluster-randomised, par-
allel group, superiority trial to evaluate the efficacy and
safety of treatment for LTBI in recent migrants within
primary care as compared to treatment in secondary
care. The primary objective will be treatment completion
(defined as taking at least 90% of antibiotic doses on pill
count). The secondary objectives of the trial will assess
adherence, acceptance of treatment, the incidence of ad-
verse effects including drug-induced liver injury (DILI),
the rates of active TB, patient satisfaction and the cost-
effectiveness of treatment.
Methods and design
Study design
This is a pragmatic cluster-randomised, parallel group, su-
periority trial of at least 20 randomisation units (20 of 60
GP Practices) in the London borough of Newham, UK.
The cluster-randomised design was chosen because
the delivery of LTBI management in primary care pro-
vided by multiple health care professionals across vari-
ous locations occurs at the level of the cluster. The use
of individual randomisation was not feasible because it
would disrupt the delivery of a complex intervention at
participating GP practices. This protocol follows the
SPIRIT guidelines [10].
Setting/intervention
The trial compares two models of care for LTBI treat-
ment: management in the community by a GP and com-
munity pharmacist (intervention) or in secondary care
by a TB doctor and TB nurse (control). The setting will
be the London borough of Newham.
Since 2014, all GP practices (n = 60) in Newham have
been contracted to screen and treat recent migrants for
LTBI as a pilot site for the national LTBI screening and
treatment programme. Eligible patients are those aged
16–35 years, from a country with a TB incidence > 150
per 1,000,000 per year or sub-Saharan Africa, who have
arrived in the UK within the last 5 years. The CATA-
PuLT study protocol mirrors the existing service specifi-
cation for the Newham LTBI programme. Nationally the
model for LTBI care in recent migrants is to screen in
primary care and to refer those with positive results to
secondary care for assessment and treatment.
In the CATAPuLT trial, all GP practices will continue
to screen eligible patients for LTBI. Practices will be ran-
domised to either provide assessment and treatment for
LTBI in primary care (the intervention arm) or to refer
patients to secondary care (the control arm, which rep-
resents the current standard of care). The test for LTBI
is an interferon gamma release assay (IGRA).
To confirm a diagnosis of LTBI, any patient with a
positive IGRA must be reviewed by a doctor to exclude
active TB. The medical assessment includes a history,
physical examination, a chest radiograph and blood tests
(full blood count, liver function tests, urea and electro-
lytes, c-reactive protein and blood-borne virus serology
(Human Immunodeficiency Virus (HIV), Hepatitis B
Virus (HBV) and Hepatitis C Virus (HCV)). Those diag-
nosed with LTBI are offered treatment with 3 months of
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Rifinah®, combination rifampicin and isoniazid therapy
(Sanofi, UK), and pyridoxine.
In the intervention arm, the GP excludes active TB,
and offers treatment for LTBI. The patient is asked to
select one accredited community pharmacy for treat-
ment. The borough has 16 community pharmacies that
have been trained and accredited to provide LTBI treat-
ment. Treatment is initiated and monitored by a com-
munity pharmacist. At their initial visit, the community
pharmacist will counsel the patient about LTBI treat-
ment. The patient is then issued with a 1 month supply
of medication and asked to attend for liver function tests
(LFTs) after 2–4 weeks. The patient attends the phar-
macy at the end of each of the 3 months of treatment to
assess adherence and adverse effects. In the control arm,
the TB clinician and TB nurse mirror the role of the GP
and community pharmacist respectively. Prior to starting
treatment, a questionnaire will be used to assess know-
ledge about LTBI.
Follow up is identical in trial both arms: at the end of
each month of treatment adherence is assessed using a
pill count (or self-report if the patient fails to attend
with their tablets), and the Medication Adherence Re-
port Scale (MARS-5), a set of 5 statements about com-
mon patterns of adherence rated on a 5-point Likert
scale (1 = always, 2 = often, 3 = sometimes, 4 = rarely, and
5 = never) [11]. At the first and second visits, urine is
tested for metabolites of isoniazid (Isoscreen®, GFC
Diagnostics, Oxfordshire, UK). At the second visit, the
patient completes a satisfaction questionnaire. Prior to
starting treatment, a questionnaire will be used to assess
knowledge about LTBI. See Table 1.
Inclusion criteria
Patients identified with LTBI aged 16–35 and who have
entered the UK within the last 5 years, from a country
with a WHO-estimated annual TB incidence of ≥150
per 100,000 per year or sub-Saharan Africa. LTBI is de-
fined as a positive IGRA test without symptoms, physical
signs or radiological evidence of active TB.
Between October 2017 and April 2018, Newham CCG
piloted extended eligibility criteria to include those who
had been resident in the UK for up to 10 years. The trial
protocol was amended to mirror this change.
Exclusion criteria
 Pregnant or breastfeeding women.
 Patients requiring medications that cannot be safely
taken with Rifinah
 HIV infection
 Individuals with known liver disease, or abnormal
liver function tests (LFTs).
 Diagnosis of cirrhosis
 Chronic or active HBV or HCV infection.
 Previous treatment for TB or LTBI
 Individuals who are unable to consent or who would
usually be offered LTBI treatment under DOT
 Evidence of active TB (based on history,
examination, blood tests and/or chest radiograph).
These exclusion criteria match the service specification
for the existing local LTBI programme. IGRA positive
patients with complex co-morbidities or health needs
are referred to specialist TB services for assessment and
treatment.
Outcomes
Primary outcome –treatment completion
Completion of at least 90% of prescribed therapy as
assessed by pill count. Where a patient fails to bring
their medication, information will be obtained by pa-
tient report. Treatment completion will be assessed at
the final patient review, approximately 3 months after
treatment is commenced. To avoid bias, an independ-
ent researcher, blinded to allocation, will verify treat-
ment completion where there is uncertainty. This
outcome is defined for IGRA positive patients who
accept treatment.
Table 1 Timetable of assessments in the CATAPuLT Trial. For Urine testing a minimum of two urine tests should be performed
during the 3 months of treatment. These should be done at the review visit for months 1 and 2 of treatment, although the second
may be done at the final visit instead if the patient was unable to provide a sample at either of the earlier visits, or additionally at
the final visit if there are concerns about adherence, *LFTs Liver function test, **INH Isoniazid
Assessment Tool Day 0 Day 15 Day 30 Day 60 Day 90
Questionnaire (Understanding and knowledge of LTBI) X
Blood tests for LFTs* X
Pill count / MARS5 tool X X X
Questionnaire (adherence/ adverse effects) X X X
Urine test (Colour and INH **metabolites) X X
Patient satisfaction questionnaire X
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Secondary outcomes
 Proportion of participants completing < 80, 80–89.9,
≥90% of antibiotic dosages based on pill count.
 Treatment adherence assessed using the five-point
adherence questionnaire (MARS5 tool), prescription
collection and a point-of-care urine testing for me-
tabolites of Isoniazid (Isoscreen) at monthly
intervals.
 Treatment acceptance assessed by calculating the
proportion of eligible patients that accept therapy;
this is defined as those initiating treatment and
attending TB clinics and community pharmacies on
at least one occasion.
 The number of patients on treatment having adverse
events including DILI leading to discontinuation of
treatment or hospitalisation. Safety of treatment will
be assessed every month by the pharmacist in
primary care and by the TB nurse in secondary care.
 The incidence of active TB occurring within 2 years
after enrolment. TB incidence in the intervention
and control group will be compared and there will
be a sub-group analysis to evaluate the effect of the
intervention in those who did or did not complete
treatment. This will be performed through matching
the study population with the national Enhanced TB
Surveillance System, where information on all re-
ported TB cases nationally are recorded.
 Assessment of patient satisfaction.
 Evaluation of cost-effectiveness of LTBI treatment in
primary care compared to secondary care.
Additional outcomes
Identification of factors associated with treatment non-
acceptance and completion using a standardised ques-
tionnaire to explore patients’ understanding and know-
ledge of LTBI.
Sample size
We predict treatment completion in primary care to im-
prove by 15% compared with secondary care (from 70 to
85%). To detect this difference with 80% power, and 5%
significance level, an individually randomised trial would
require 268 participants. We planned to conduct our
trial in a minimum of 20 GP practices (10 intervention
and 10 control), noting that as the number of GP prac-
tices increases, the required total sample size of individ-
ual participants falls. With 20 practices, we would have
needed to adjust for the effect of clustering by increasing
the sample size to 780 participants (or 39 patients per
practice) assuming an ICC of 0.05. To allow for loss to
follow up and treatment non-acceptance we would have
inflated the required sample size by 30% to 1014 partici-
pants (51 per GP practice). The final number of
practices randomised was 34, though as 14 were ran-
domized after the initial phase we expect variability in
cluster size reflected by a coefficient of variation of 0.5.
Under the same assumptions as before the number of
individuals required providing the primary outcome is
442 (221 per arm), inflated due to loss to follow up and
treatment non-acceptance to 576 (17 per practice).
Consent
Valid implied consent is assumed for participation, an
approach used in two other recent trials in TB and HIV
screening in London [12, 13] . All eligible patients are
given a patient information sheet (PIS) in English and
six other languages.
Eligible patients are asked for verbal consent to access
their data which will be recorded in their electronic pa-
tient records. The PIS explains how patient data is col-
lected and how patients may opt out of the study.
Our approach to consent was formally approved in
our ethics application (see “Ethics approval”).
Recruitment
It is expected that most eligible patients will be offered
testing for LTBI at a “new patient check”, usually per-
formed by a health care assistant or qualified nurse
shortly after a patient registers with a GP practice. Pa-
tients will be given a PIS about the CATAPuLT trial
when offered testing for LTBI.
The trial will also recruit eligible patients who are
already registered with a GP. They will be given a PIS
when offered an IGRA blood test. Eligible IGRA-positive
patients tested prior to the trial opening who have not
yet had a follow up appointment will be given a PIS and
managed as per the arm of their GP practice. Eligible
IGRA-positive patients tested prior to the trial opening
who have had a follow up appointment but no prescrip-
tion for treatment issued may be given a PIS and man-
aged as per the arm of their GP practice. This group will
be treated as a separate cohort and analysed separately
from the main trial.
Cluster-level data about the number of positive tests
recorded at each site will be monitored to ensure that all
eligible patients are asked for consent to share their data
with the trial team.
Randomisation
Twenty GP practices were initially recruited and rando-
mised, but after participant recruitment rates were lower
than expected further practices were randomised across
three further phases as practices became ready to join
the trial. In the initial phase, 20 GP practices were strati-
fied for randomisation by the cross-classification of two
binary factors based on practice size and number of
IGRA positives identified previously.
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There were three further phases of randomisation for
practices 21–22, 23–29 and 30–34 respectively. Of these,
the randomisation of practices 23–29 was stratified by
the number of IGRA positives and in the other phases
randomisation was unrestricted. Practices 23–29 were
randomised with the allocation of 3 to one study arm
and 4 to the other (determined at random). In the final
phase the allocation was 2 to one study arm and 3 to the
other, allocating 3 to the arm that was allocated only 3
in the third phase, to ensure an overall 1:1 allocation of
17 practices to each arm. At all phases and within all
strata the randomisation was implemented through ran-
dom permutation using STATA v15 (STATA Corpor-
ation, College Station, Texas, USA). Randomisation was
conducted by the trial statistician (AC). Information
about study sites can be obtained from the correspond-
ing author or chief investigator.
Blinding
Data collection and analysis will be unblinded due to the
nature of the intervention, cluster level randomisation
and different data collection systems for the two study
arms.
Data collection methods and management
Study tools
Patient satisfaction and adverse effects will be assessed
using non-validated questionnaires. Patient knowledge
about LTBI will be assessed using a non-validated ques-
tionnaire adapted from two previous studies [14, 15].
The MARS-5 adherence questionnaire has not been vali-
dated for use in LTBI [11]. The Isoscreen® point of care
test for metabolites of isoniazid (GFC Diagnostics, Ox-
fordshire, UK) has been validated in small prospective
studies with a sensitivity of greater than 90% and a spe-
cificity of greater than 95% [16–18].
Data collection and management
Patient data will be entered electronically by the patients’
usual care team. All data collection will use purpose-
built electronic management templates, adapted those
developed for the national LTBI screening programme
by the Clinical Effectiveness Group, Queen Mary Uni-
versity of London for Public Health England (PHE) [19].
Data will be managed and stored in accordance with
local and national information governance specifications.
Analysis
All analyses will be conducted on an intention-to-treat
basis. The analysis will include all eligible participants
regardless of how well the GP practice followed the
study protocol or how well the participant complied
with their treatment plan. The analysis will exclude any
patients however who have withdrawn from the trial and
specified they do not wish their data to be analysed.
Some outcomes are only applicable for certain sub-
groups. The primary outcome is defined only for patients
who accept treatment. Patient satisfaction is only defined
for patients who are still under care at 2 months, when
the satisfaction questionnaire is administered. The MARS-
5 and isoniazid metabolite urine testing adherence mea-
sures are only applicable at times when the patient is still
taking treatment, i.e. not stopped due to adverse effects or
by patient choice/withdrawal from the trial.
The primary outcome will be analysed using a logistic
regression model. Results will be reported as odds ratios
(OR) for the intervention compared to control with their
corresponding 95% confidence intervals (CI) and two-
sided p-values. The ICC for the primary outcome will be
reported. Similarly, across the secondary outcomes treat-
ment effect estimates will be presented with 95% confi-
dence intervals based on regression models, using binary
logistic regression, ordinal logistic regression or linear
regression as appropriate. Regression models will include
random intercept effects for GP practice.
Adjusted effect measures are considered the primary
effect measures; unadjusted measures will also be re-
ported. We will adjust the analyses for practice size and
number of previous IGRA positives, our stratification
factors, and selected pre-determined participant factors
considered predictive of treatment completion.
Missing data
Some patients will inevitably be lost to follow-up, arising
primarily because they have withdrawn from treatment.
For the primary outcome, a patient who withdraws from
treatment without collecting all prescriptions will be
classified as having failed treatment. We will impute
missing data for those patients that collect all prescrip-
tions but miss the final visit using multiple imputation
by chained equations (MICE). A sensitivity analysis will
also be performed in this group in which those failing to
attend a final visit are assumed to have failed treatment.
Health economic analysis
We will evaluate the cost-effectiveness of LTBI manage-
ment in recent migrants within primary care settings as
compared to secondary care settings using the trial co-
hort. A decision-tree model will be developed to com-
pare the two strategies in terms of cost-effectiveness
(cost/LTBI case treated). The methods of economic
evaluation will follow the standard NICE reference case
[20]. The analysis will be conducted from an NHS per-
spective with a two-year time horizon and standard dis-
counting of costs and outcomes applied (3.5% per
annum). The decision analysis model will describe the
possible pathways of patients at the different time point
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of adherence control (t = 15, 30, 60, and 90 days) under
each strategy: lost to follow-up, or ongoing treatment.
Estimates of the costs of LTBI screening, LTBI treat-
ment, management of adverse effects, and diagnosis of
active TB will be obtained from the NHS Reference
Costs [21]. Sensitivity analyses will be conducted to
evaluate the impact of parameters on the results.
Harms
The intervention in this trial is the setting of care. There
are no specific anticipated harms associated with alloca-
tion within the trial. However, patients in both arms of
the trial will be treated for LTBI with a 3-month course
of daily Rifinah®. This preparation is licenced for use in
the UK and is currently recommended for LTBI [20, 22].
Trial participants will be monitored for adverse events
(AEs) and serious adverse events (SAEs) at each monthly
review and are asked to undertake a blood test to assess
liver function after 2 to 4 weeks of treatment.
Ethics approval
Ethical approval for the trial was obtained from the Cam-
den & Kings Cross Research Ethics Committee (REC),
London, United Kingdom on the 11th March 2016. Proto-
col version and date: version 8, 13 August 2019.
Patient and public involvement
Increasing patient choice and improving patient experi-
ence underlie the central hypothesis of the trial. The
intervention enables patients to select an accredited
pharmacy most convenient for them geographically and
to attend outside office hours and at weekends in con-
trast to the specialist TB service. Prior to the design of
the trial interviews were conducted with patients who
had been treated for LTBI in the pilot service in New-
ham. The trial is supported by the chair of the “Patient
Panel” at Barts Health NHS Trust and the local branch
of Healthwatch, the independent consumer champion
for health and social care in England. All questionnaires
in the trial were piloted with eligible patients.
Trial organisation
The trial will not have a data monitoring committee
based on an assessment of risk (low). The trial will be
overseen by a Trial Management Group (TMG) that will
meet regularly until the end of the trial. The TMG will
consist of the chief investigator, the trial team and co-
investigators and collaborators.
Study schedule and trial status
The first participant was enrolled in January 2017.
The trial will remain open for data collection until
December 2019.
Dissemination
Trial results will be reported in scientific manuscripts
for publication and disseminated through charities,
stakeholder organisations and patient groups.
Discussion
The WHO’s End TB Strategy and the Lancet Commis-
sion on TB both emphasise that there is an urgent need
to make TB care patient-centred and that there is a lack
of implementation research evidence to guide policy-
makers in how to achieve this goal [2, 23]. It is also rec-
ognized that TB research must be “migrant-inclusive”
[24]. This trial seeks to provide such evidence by evalu-
ating the efficacy, safety and cost-effectiveness of a novel
model of care for recent migrants to the UK with LTBI.
We will assess whether this model of care results in
higher rates of LTBI treatment completion. To our
knowledge this is the only trial currently investigating
novel models of care in the delivery of LTBI treatment.
The results of the trial will inform national policy on the
delivery of LTBI care to recent migrants in the UK but
may be generalizable to other high-income settings and
other groups with LTBI, such as recent contacts of ac-
tive disease.
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